Pre–I-O (1 January 2010–31 March 2016) | Post–I-O (1 April 2016–30 June 2019) | |||||
---|---|---|---|---|---|---|
All (N = 690)a | NSQ (n = 500) | SQ (n = 87) | All (N = 326)b | NSQ (n = 243) | SQ (n = 57) | |
Age,c years | ||||||
Median Q1–Q3 Range | 65 57–72 29–91 | 65 56.5–72.5 29–91 | 66 62–72 39–80 | 66 59–73 31–90 | 65 58–73 31–90 | 70 64–72 43–84 |
Female, n (%) | 380 (55.1) | 296 (59.2) | 36 (41.4) | 177 (54.3) | 148 (60.9) | 16 (28.1) |
Initial TNM stage, n (%) | ||||||
I–IIIAd | 66 (9.6) | 36 (7.2) | 17 (19.5) | 38 (11.7) | 22 (9.1) | 15 (26.3) |
IIIB | 86 (12.5) | 59 (11.8) | 19 (21.8) | 38 (11.7) | 21 (8.6) | 14 (24.6) |
IV | 538 (78.0) | 405 (81.0) | 51 (58.6) | 250 (76.7) | 200 (82.3) | 28 (49.1) |
Location of metastases, n (%) | ||||||
Visceral, excl. adrenal/liver | 164 (23.8) | 132 (26.4) | 12 (13.8) | 77 (23.6) | 63 (25.9) | 9 (15.8) |
Bone | 94 (13.6) | 80 (16.0) | 6 (6.9) | 50 (15.3) | 43 (17.7) | < 5 |
Liver | 47 (6.8) | 35 (7.0) | < 5 | 16 (4.9) | 13 (5.3) | < 5 |
Brain | 44 (6.4) | 39 (7.8) | < 5 | 39 (12.0) | 34 (14.0) | < 5 |
Lymph | 39 (5.7) | 26 (5.2) | 7 (8.0) | 21 (6.4) | 15 (6.2) | < 5 |
Adrenal | 25 (3.6) | 17 (3.4) | < 5 | 13 (4.0) | 13 (5.3) | 0 (0.0) |
CCI, n (%) | ||||||
0 | 234 (33.9) | 171 (34.2) | 25 (28.7) | 108 (33.1) | 89 (36.6) | 14 (24.6) |
1 | 165 (23.9) | 118 (23.6) | 30 (34.5) | 72 (22.1) | 50 (20.6) | 19 (33.3) |
2 | 69 (10.0) | 47 (9.4) | 14 (16.1) | 27 (8.3) | 18 (7.4) | 6 (10.5) |
3 | 91 (13.2) | 68 (13.6) | 8 (9.2) | 39 (12.0) | 26 (10.7) | 11 (19.3) |
4 + | 131 (19.0) | 96 (19.2) | 10 (11.5) | 80 (24.5) | 60 (24.7) | 7 (12.3) |
First-line treatment, n (%) | ||||||
Platinum-based chemotherapy | 491 (71.2) | 331 (66.2) | 77 (88.5) | 189 (58.0) | 123 (50.6) | 46 (80.7) |
Tyrosine kinase inhibitor | 154 (22.3) | 141 (28.2) | < 5 | 104 (31.9) | 100 (41.2) | < 5 |
Non-platinum chemotherapy | 38 (5.5) | 23 (4.6) | 7 (8.0) | 5 (1.5) | < 5 | < 5 |
I-O therapy | < 5 | < 5 | 0 (0.0) | 27 (8.3) | 16 (6.6) | 7 (12.3) |
Other monoclonal antibodies | 6 (0.9) | < 5 | < 5 | < 5 | 0 (0.0) | < 5 |
Duration of first-line treatment, n (%) | ||||||
< 1 month | 136 (19.7) | 78 (15.6) | 27 (31.0) | 41 (12.6) | 20 (8.2) | 15 (26.3) |
1– < 3 months | 328 (47.5) | 228 (45.6) | 54 (62.1) | 132 (40.5) | 90 (37.0) | 34 (59.6) |
3– < 6 months | 103 (14.9) | 84 (16.8) | < 5 | 71 (21.8) | 60 (24.7) | 6 (10.5) |
6– < 12 months | 61 (8.8) | 53 (10.6) | < 5 | 49 (15.0) | 44 (18.1) | < 5 |
≥ 12 months | 62 (9.0) | 57 (11.4) | < 5 | 32 (9.8) | 28 (11.5) | < 5 |
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | < 5 | < 5 | 0 (0.0) |